But, But, But, I Thought You Were for Sale?

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Earlier this month, BioSante Pharmaceuticals' (Nasdaq: BPAX  ) Chief Executive Officer Stephen Simes told Bloomberg there were "many, many companies" interested in the BioSante's female libido drug, LibiGel. The way the article read, it sounded like a licensing deal worth $100 million upfront or that possibly a complete takeout was imminent.

I guess not.

BioSante announced today that it is raising $45 million by selling 16 million shares at $3.00 a pop. That's a 17% increase in the share count at a 3% discount to yesterday's closing price, which certainly doesn't look like tide-us-over-until-we-get-a-deal-done money to me.

What have we learned from this? Sticking a for-sale sign on the front lawn isn't enough to find a buyer. It didn't work for Biogen Idec (Nasdaq: BIIB  ) a few years ago. Forest Labs (NYSE: FRX  ) bought Clinical Data but for less than the company was worth the day before. At least management didn't go that route.

As I said previously, companies that sell erectile dysfunction drugs -- Pfizer (NYSE: PFE  ) , Eli Lilly (NYSE: LLY  ) , Bayer, and GlaxoSmithKline (NYSE: GSK  ) -- are all potential licensors of LibiGel. But given the history of failures for female libido drugs, it would be risky for them to buy in before the safety and efficacy are confirmed.

We also learned that BioSante isn't the best market timer. Raising capital earlier this month when shares briefly touched $4.00 per share would have been a lot less costly for investors. Maybe "many, many" deals were in the works then and they all fell through. Or maybe management was hoping shares would go higher.

Welcome to the club.

Interested in small companies? Grab this free report from Motley Fool analysts: "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Click here to see his holdings and a short bio. The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services have recommended buying shares of GlaxoSmithKline and Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1527185, ~/Articles/ArticleHandler.aspx, 10/23/2016 5:49:36 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
ANIP $66.33 Down -0.44 -0.66%
ANI Pharmaceutical… CAPS Rating: **
BIIB $290.65 Down -9.01 -3.01%
Biogen CAPS Rating: *****
FRX.DL $0.00 Down +0.00 +0.00%
Forest Laboratorie… CAPS Rating: ****
GSK $41.13 Down -0.30 -0.72%
GlaxoSmithKline CAPS Rating: ***
LLY $78.25 Down -0.49 -0.62%
Eli Lilly and Co. CAPS Rating: ***
PFE $32.18 Down -0.36 -1.11%
Pfizer CAPS Rating: ****